Insulet Co. (NASDAQ:PODD) Shares Sold by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. lowered its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 7.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,400 shares of the medical instruments supplier's stock after selling 2,000 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Insulet were worth $6,670,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new position in Insulet in the 4th quarter worth $36,000. Itau Unibanco Holding S.A. purchased a new stake in shares of Insulet during the fourth quarter worth about $42,000. SRS Capital Advisors Inc. lifted its stake in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after acquiring an additional 56 shares in the last quarter. Assetmark Inc. lifted its stake in shares of Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after acquiring an additional 246 shares in the last quarter. Finally, Coppell Advisory Solutions LLC boosted its holdings in Insulet by 135.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock valued at $74,000 after purchasing an additional 162 shares during the last quarter.

Insulet Stock Performance

Shares of Insulet stock traded down $2.20 during trading on Tuesday, hitting $304.39. 591,849 shares of the stock were exchanged, compared to its average volume of 711,884. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 12 month low of $173.00 and a 12 month high of $329.33. The stock's fifty day moving average is $288.34 and its 200 day moving average is $275.34. The stock has a market cap of $21.42 billion, a PE ratio of 52.57, a P/E/G ratio of 3.62 and a beta of 1.37.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The company had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.73 earnings per share. As a group, sell-side analysts anticipate that Insulet Co. will post 3.92 EPS for the current year.

Analyst Ratings Changes

PODD has been the topic of a number of recent analyst reports. The Goldman Sachs Group started coverage on Insulet in a research report on Friday, May 30th. They issued a "buy" rating and a $380.00 target price on the stock. Oppenheimer upped their price target on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Wells Fargo & Company set a $322.00 price objective on shares of Insulet in a report on Monday, April 28th. Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Finally, Royal Bank of Canada assumed coverage on shares of Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price target on the stock. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $321.00.

Insider Transactions at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president now owns 23,180 shares of the company's stock, valued at $7,382,134.60. This represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. This represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.